Evidence map›Paper›PMID 36585899›Full record

ArticleBrain and behavior2023

The combination of Astragalus membranaceus and ligustrazine mitigates cerebral ischemia-reperfusion injury via regulating NR2B-ERK/CREB signaling.

Xialing Tang, Shanshan Xie, Huajun Wang, Yingbin Li, Zhiyu Lai, Shuangxi Sun, Ruanhuan Pan, Yan Huang, Jun Cai

Open access · goldAbstract read
In one paragraph

Article in Brain and behavior, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Xialing TangThe Second Institute of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
Shanshan XieThe Second Institute of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
Huajun WangThe Second Institute of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
Yingbin LiThe Second Institute of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
Zhiyu LaiThe Second Institute of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
Shuangxi SunThe Second Institute of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
Ruanhuan PanThe Second Institute of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
Yan HuangThe Second Institute of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
Jun CaiThe Second Institute of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.ORCID 0000-0002-5959-3264
Guangzhou University of Chinese Medicine · CN

Funding

Guangdong Provincial Key Laboratory of Chinese Medicine on Emergency in Traditional Chinese Medicine 2017B030314176Guangdong Provincial Key Laboratory of Chinese Medicine on Prevention and Treatment of Refractory Chronic Diseases 2018B030322012Innovation and Strong University Project of Guangzhou University of Traditional Chinese Medicine 2017KTSCX039National Natural Science Foundation of China 81804038National Natural Science Foundation of China 81873262Project of Administration of Traditional Chinese Medicine of Guangdong Province of China 20211157
6 · The paper itself

Abstract

background and purposeCerebral ischemia-reperfusion (I/R) injury is a major factor underlying the high mortality and morbidity rates in stroke patients. Our previous study found that the combination of Astragalus membranaceus extract and ligustrazine (Ast+Lig) treatment could protect brain tissues against inflammation in rats with thrombolytic cerebral ischemia. Activation of N-methyl-D-aspartate receptors (NMDAR) is implicated in brain damage induced by cerebral I/R injury.

methodsWe used in vivo and in vitro models of cerebral I/R injury for middle cerebral artery occlusion/reperfusion in mice and oxygen-glucose deprivation/reoxygenation in primary rat cerebral cortical neurons to evaluate the protective effects of Ast+Lig on cerebral I/R injury, and whether the protective mechanism was related to the regulation of NMDAR-ERK/CREB signaling.

resultsTreatment with Ast+Lig, or MK-801 (an inhibitor of NMDAR) significantly ameliorated neurological deficits, decreased infarct volumes, suppressed neuronal damage and Ca

conclusionsThe overall results thus suggest that the Ast+Lig combination conferred neuroprotective properties against cerebral I/R injury via regulation of the NR2B-ERK/CREB signaling pathway.

Indexed as

Brain IschemiaNeuroprotective AgentsReperfusion InjuryAnimalsAstragalus propinquusInfarction, Middle Cerebral ArteryMicePyrazinesRatsReceptors, N-Methyl-D-AspartateSignal TransductionNeuroprotective AgentsPyrazinesReceptors, N-Methyl-D-AspartatetetramethylpyrazineAstragalus membranaceuscerebral ischemia-reperfusion injuryligustrazineN-methyl-D-aspartate receptorsstroke

Identifiers

PMID36585899
PMCPMC9927841
OpenAlexW4313339538

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.